Short-course instead of long-course chemotherapy for smear-negative patients in sub-Saharan Africa

International Journal of Tuberculosis and Lung Disease

Volumn 5, Issue 1, 2001, Pages 4-11

  Van Gorkom, J ^a   Van Cleeff, M ^a   Becx Bleumink, M ^a   Veen, J ^a  

^a KNCV TUBERCULOSIS FOUNDATION   (Netherlands)

Author keywords

Short course chemotherapy; Sputum smear negative; Sub Saharan Africa; Tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; THIOACETAZONE;

AFRICA; CHEMOTHERAPY; DRUG BIOAVAILABILITY; DRUG COST; HEALTH CARE SYSTEM; HEALTH PROGRAM; HUMAN; PRIORITY JOURNAL; REVIEW; SHORT COURSE THERAPY; SPUTUM EXAMINATION; TREATMENT PLANNING; TUBERCULOSIS;

AFRICA SOUTH OF THE SAHARA; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTITUBERCULAR AGENTS; COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; HUMANS; NATIONAL HEALTH PROGRAMS; OUTCOME ASSESSMENT (HEALTH CARE); RIFAMPIN; SPUTUM; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 0035038606     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. The mutual assistance programme of the IUATLD. Development, contribution and significance
2. Framework for effective tuberculosis control
3. Treatment of Tuberculosis
4. Cutaneous hypersensitivity reactions to thiacetazone in HIV-1 seropositive patients treated for tuberculosis
5. The supply of anti-tuberculosis drugs: Price evolution
6. A review of the diagnosis and treatment of smear-negative pulmonary tuberculosis
7. Tuberculosis control in resource-poor countries: Alternative approaches in the era of HIV
8. An approach to the problems of diagnosing and treating adult smear-negative pulmonary tuberculosis in high-HIV-prevalence settings in sub-Saharan Africa
9. Isoniazid with thiacetazone (thioacetazone) in the treatment of pulmonary tuberculosis in East Africa. Third Report of Fifth Investigation. A co-operative study in East Africian hospitals, clinics and laboratories with the collaboration of the East African and British Medical Research Councils
10. The therapy of pulmonary tuberculosis in Kenya: A comparison of the results achieved in controlled clinical trials with those achieved by the routine treatment services
11. Studies on the treatment of tuberculosis. British Medical Research Council Tuberculosis Units, 1946-1986
12. A controlled trial of 3-month, 4-month, and 6-month regimens of chemotherapy for sputum-smear-negative pulmonary tuberculosis: Results at 60 months
13. A controlled trial of a 2-month, 3-month and 12-month regimen of chemotherapy for sputum-smear-negative pulmonary tuberculosis: The results at 30 months
14. Sputum smear-negative pulmonary tuberculosis: Controlled trial of 3-month and 2-month regimens of chemotherapy. First Report
15. A controlled trial of 2-month, 3-month, and 12-month regimens of chemotherapy for sputum-smear-negative pulmonary tuberculosis. Results at 60 months
16. An economic evaluation of alternative programme designs for tuberculosis control in rural Uganda
17. Will DOTS do it? A reappraisal of tuberculosis control on countries with high rates of HIV infection
18. Case-notification data from National Tuberculosis Programmes, Malawi, Tanzania, Kenya, 1985-1999
19. Treatment outcome of an unselected cohort of tuberculosis patients in relation to human immunodeficiency virus serostatus in Zomba hospital, Malawi
20. An epidemiological study of tuberculosis and HIV infection in Tanzania, 1991-1993
21. HIV sero-prevalence among tuberculosis patients in Kenya
22. Cohort study of human immuno-deficiency virus infection in patients with tuberculosis in Nairobi, Kenya
23. The impact of human immunodeficiency virus on mortality of patients treated for tuberculosis in a cohort study in Zambia
24. Randomised trial of thiacetazone and rifampicin-containing regimens for pulmonary tuberculosis in HIV-infected Ugandans
25. The impact of human immunodeficiency virus on response to treatment and recurrence rate in patients treated for tuberculosis: Two-year follow-up of a cohort in Lusaka, Zambia
26. Anti-tuberculosis drug resistance in the world
27. Anti-tuberculosis drug resistance in the world
28. Community contribution to tuberculosis care in countries with high tuberculosis prevalence: Past, present, and future
29. Evaluation of a unified treatment regimen for all new cases of tuberculosis using guardian-based supervision
30. Direct observation of tuberculosis treatment by supervised family members in Yasthorn Province, Thailand
31. Results of directly observed short-course chemotherapy in 112 842 Chinese patients with smear-positive tuberculosis
32. High-compliance tuberculosis treatment programme in a rural community
33. High cure rates in smear-positive tuberculosis patients using ambulatory treatment with once-weekly supervision during the intensive phase in Sulawesi, Republic of Indonesia
34. DOTS for tuberculosis: Results from a randomised controlled trial in Pakistan show no additional benefit from direct observation of treatment
35. Randomised controlled trial of self-supervised and directly observed treatment of tuberculosis
36. Directly observed therapy and treatment adherence
37. Quality assurance of fixed-dose combinations of anti-tuberculosis medications
38. Extra-pulmonary and disseminated tuberculosis in HIV-1-seropositive patients presenting to the acute medical services in Nairobi
39. The mortality and pathology of HIV infection in a West African city